Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2604)	9/25/2009 12:48:17 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

ZIOP traded at a 52wks H as it went easily through the resistance from its Aug 7 H of $2.25 <g> The stock is still up 19.43% on volume of > 361,700 about 8x its ADV bigcharts.marketwatch.com Earlier this month it raised $5.05M in a private placement and it also presented at Rodman & Renshaw 11th Annual Healthcare Conference on Sep 10 ZIOP is currently focused on 3 clinical programs: Palifosfamide, or ZIO-201 for treating sarcoma, lymphoma, testicular, and other cancers.It delivers only the cancer fighting component of ifosfamide and is expected to overcome the resistance seen with ifosfamide and cyclophosphamide.It also doesn't have the toxic metabolites of ifosfamide.It is on a PII to treat unresectable or metastatic soft tissue sarcoma. Indibulin,or ZIO-301 is an oral tubulin binding agent that targets both mitosis and cancer cell migration.It's expected benefits, besides oral dosing, is that it has no neuropathy and minimal overall toxicity.It is in several PIs in cancer patients as a single agent and in combination with other drugs. Darinaparsin, or ZIO-101 is an organic arsenic being developed for the treatment of various hematologic and solid cancers.It is considerably less toxic than inorganic arsenic,particularly with regard to cardiac toxicity.It is in PI and PII for solid tumors and hematological Cas.Ther have been some favorable results on trials with its IV-administration in lymphoma,that were reported at ASCO in May.The oral form reportedly is active and well tolerated. ZIOP has been trimming its loss in the last 4Qs.It has NSLTD, the ACTAY is $3, but with some good news it seems that the stock could get to the $4 level.<g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2604)	9/28/2009 9:52:29 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

TPI named a marketing specialist as CEO.<g> Mr.Tao Yang, age 42, is a well-known certified pharmaceutical sales training specialist with more than 18 years experience in the sales and marketing industry. His experience includes serving as a sales training specialist and marketing manager for Astra Zeneca and Bayer, in addition to managing the training services for 85 well-known domestic and international pharmaceutical companies during the past ten years. These include Grunenthal-San Huan Pharmaceutical (China) Co., Ltd., Beaufour Ipsen Pharmaceutical Co., Ltd., and Yangtze River Pharmacy Group, etc. Mr. Yang also served as BPIP implementation consultant for CPDF, launched by the World Bank in 2001, and the executive advisor of a policy system program in 2007, which is a training system formed by the Chinese and British government aiming to support domestic small to medium sized businesses. TPI has been making all time Hs lately. It needs to close above $4.25 in order to test its Sep 2 all time H at $4.30 I still will keep my target at $5 <g> bigcharts.marketwatch.com Bernard